Identification of Immuno-Inflammation-Related Biomarkers for Acute Myocardial Infarction Based on Bioinformatics
Hongjun You,Mengya Dong
DOI: https://doi.org/10.2147/JIR.S421196
IF: 4.5
2023-08-08
Journal of Inflammation Research
Abstract:Hongjun You, Mengya Dong Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710068, People's Republic of China Correspondence: Mengya Dong, Department of Cardiovascular Medicine, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710068, People's Republic of China, Tel +86-15802943974, Email Purpose: Previous studies have confirmed that inflammation and immunity are involved in the pathogenesis of acute myocardial infarction (AMI). However, only few related genes are identified as biomarkers for the diagnosis and treatment of AMI. Patients and Methods: GSE48060 and GSE60993 datasets were retrieved from Gene Expression Omnibus. The differentially expressed immuno-inflammation-related genes (DEIIRGs) were obtained from GSE48060, and the biomarkers for AMI were screened and validated using the "Neuralnet" package and GSE60993 dataset. Further, the biomarker-based nomogram was constructed, and miRNAs, transcription factors (TFs), and potential drugs targeting the biomarkers were explored. Furthermore, immune infiltration analysis was analyzed in AMI. Finally, the biomarkers were verified by assessing their mRNA levels using real-time quantitative PCR (RT-qPCR). Results: First, eight biomarkers were screened via bioinformatics, and the artificial neural network model indicated a higher prediction accuracy for AMI even in the validation dataset. Nomogram had accurate forecasting ability for AMI as well. The TFs GTF2I, PHOX2B, RUNX1, and FOS targeting hsa-miR-1297 could regulate the expressions of ADM and CBLB , and RORA could effectively interact with melatonin and citalopram. RT-qPCR results for ADM, PI3, MMP9, NRG1 and CBLB were consistent with those of bioinformatic analysis. Conclusion: In conclusion, eight key immuno-inflammation-related genes, namely, SH2D1B, ADM, PI3, MMP9, NRG1, CBLB, RORA , and FASLG , may serve as the potential biomarkers for AMI, in which the downregulation of CBLB and upregulation of ADM, PI3 , and NRG1 in AMI was detected for the first time, providing a new strategy for the diagnosis and treatment of AMI. Keywords: acute myocardial infarction, immune-related gene, inflammation-related gene, biomarker, nomogram Acute myocardial infarction (AMI) is the sudden irreversible necrosis of heart muscle, which commonly results from atherosclerotic plaque disruption and subsequent interruption of blood flow. 1 It is one of the heart diseases with the highest prevalence and incidence and brings enormous health and financial burdens. 2 Despite the rapid development of pharmacological and invasive treatments for AMI, particularly percutaneous coronary interventions, the admission and mortality rates are still high. 3,4 The progression of AMI to left ventricular dilatation, heart failure (HF), and sudden cardiac death still cannot be controlled. 5 Therefore, it is necessary and important to explore the pathogenesis of AMI. Inflammation and metabolic disturbance are well-accepted underlying mechanisms of AMI, and significant evidence supports that inflammation and immunity have central roles in the development and progression of AMI. 6,7 The initial acute inflammatory response in AMI is triggered by innate immune response induced by damaged myocardial cells. The active innate immune system causes the infiltration of immune cells into ischemic heart tissue and coordinates the original proinflammatory responses. 8 Based on these aspects, a variety of machine learning algorithms have been integrated to identify novel diagnostic biomarkers in AMI to characterize the possible association between biomarkers and immune cell infiltration status. For example, Li et al integrated weighted gene co-expression network analysis (WGCNA) and single-sample gene set enrichment analysis (ssGSEA) to identify candidate genes in AMI progression. 9 Immune-related genes were conducted to screen diagnostic biomarkers relevant to the pathological process of the AMI. 10 On the other hand, Wang et al identified eight miRNAs with high clinical applicability to distinguish patients with AMI from non-AMI individuals. 11 Meanwhile, there were few studies on the combination of inflammatory-related genes and immune-related genes to explore the biomarkers related to AMI recognition. In the study, the key immuno-inflammation-related genes in AMI were identified via multiple bioinformatic methods from public databases. Enrichment analysis, immune infiltration analysis, and TF–miRNA–mRNA regulatory network analysis were conducted to assess the molecular mechanism of immuno-inflammation-related genes playing roles in AMI. In addition, drugs targeting -Abstract Truncated-
immunology